Executive Summary
The 25 filings reveal a bifurcated healthcare landscape: animal health leader Zoetis faces persistent demand headwinds and cut FY2026 guidance, while diversified giants like Danaher and BD signal confidence through substantial insider equity awards. Insider selling at Pfizer and Cigna, though modest in size, contrasts with heavy insider accumulation at Danaher, suggesting divergent management conviction.
Fidelity's increased stakes in Moderna (13.1%) and Biogen (12.4%) highlight institutional conviction in large-cap biotech, while J&J's venture portfolio shows strategic bets in early-stage therapeutics. Capital allocation trends show aggressive buybacks at Zoetis (up 48% YoY) despite earnings decline, and Danaher's equity awards point to long-term incentive alignment. Key catalysts include Zoetis's guidance revision and upcoming earnings calls, while BD's results remain opaque pending further disclosure.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Filing types in this digest: 10-Q · 8-K · Schedule 13G · 13F · Form 4
Tracking the trend? Catch up on the prior S&P 500 Healthcare Sector SEC Filings digest from August 05, 2026.
Investment Signals (11)
- Zoetis ↓ (BEARISH)▲
Q2 2026 revenue flat YoY ($2,468M vs $2,474M) but net income down 4.8% ($691M vs $726M); FY2026 guidance cut to (3)%-(1)% organic revenue growth and (9)%-(5)% adjusted net income growth, signaling persistent headwinds
- Zoetis ↓ (MIXED)▲
U.S. companion animal sales declined 11% YoY due to macro-driven price sensitivity and generic competition on Cerenia/Convenia, while U.S. livestock sales grew 23% YoY on favorable beef economics and poultry vaccine demand
- Zoetis ↓ (BULLISH)▲
Aggressive share repurchases ($1,170M in H1 2026 vs $788M in H1 2025, +48%) boosted diluted EPS by 3.7% to $3.08 despite lower net income, showing commitment to shareholder returns
- Danaher ↓ (BULLISH)▲
Chairman Steven Rales awarded 500,000 shares and 1,000,000 stock options; Mitchell Rales awarded 500,000 shares and 1,000,000 options, signaling strong insider alignment and confidence in long-term value
- Moderna ↓ (BULLISH)▲
Fidelity increased stake to 13.1% (51.8M shares) as of June 30, 2026, up from prior filing, indicating institutional conviction in the biotech's pipeline
- Biogen ↓ (BULLISH)▲
Fidelity holds 12.4% stake (18.3M shares), reaffirming passive institutional support despite sector volatility
- Cigna ↓ (BEARISH)▲
Insider Jones Nicole S sold 19,436 shares (~$5.37M) at $276.27 under a 10b5-1 plan, while exercising options at $192.02, locking in gains; net selling suggests caution at current levels
- Pfizer ↓ (BEARISH)▲
SVP & Controller Jennifer Damico sold 3,278 shares (~$83K) at $25.40, a minor transaction but part of broader insider selling trend in large pharma
- BD (Becton Dickinson) (NEUTRAL)▲
Director equity awards (189 and 94 deferred shares) at $165.62, indicating routine compensation but no insider buying; Q3 FY2026 results filed without figures, limiting signal
- J&J (JJDC) (BULLISH)▲
Q2 2026 venture portfolio valued at $798.65M, with largest positions in Protagonist Therapeutics ($300.2M) and Nanobiotix ($212.0M), showing strategic bets in oncology and rare disease
- Danaher ↓ (BULLISH)▲
CFO Gugino awarded 153,563 stock options and EVP Sawyer Montgomery 245,701 options, reinforcing long-term incentive alignment across leadership
Risk Flags (8)
- Zoetis/Guidance Cut↓ [HIGH RISK]▼
FY2026 organic revenue growth lowered to (3)%-(1)% and adjusted net income growth to (9)%-(5)%, reflecting persistent market headwinds; Q2 U.S. segment revenue declined 7% YoY
- Zoetis/Margin Pressure↓ [HIGH RISK]▼
Net income declined 4.8% YoY in Q2 and 2.7% in H1 2026; restructuring charges surged 230% to $99M in H1 2026 from $30M, indicating operational strain
- Zoetis/Competition↓ [MEDIUM RISK]▼
Generic competition on key products Cerenia and Convenia drove 11% decline in U.S. companion animal sales, a structural threat to revenue
- Zoetis/Cash Flow Decline↓ [MEDIUM RISK]▼
Operating cash flow fell 5.7% to $1,056M in H1 2026 from $1,120M, while interest expense rose 15% to $123M, pressuring financial flexibility
- Cigna/Insider Selling↓ [MEDIUM RISK]▼
Insider Jones Nicole S sold $5.37M worth of stock, with net selling after option exercises, potentially signaling lack of confidence at current valuation
- Pfizer/Insider Selling↓ [LOW RISK]▼
SVP Damico sold shares at $25.40, continuing a pattern of insider sales in large pharma; though small, it adds to negative sentiment
- BD/Disclosure Opacity [MEDIUM RISK]▼
Q3 FY2026 8-K filed without specific financial figures, limiting transparency and delaying trend analysis; investors must wait for 10-Q
- Zoetis/Board Transition↓ [LOW RISK]▼
Director McCallister retired, reducing board size to 12; loss of long-tenured experience could impact governance, though no disagreement noted
Opportunities (8)
- Zoetis/International Growth↓ (OPPORTUNITY)◆
International segment grew 8% reported (6% organic), led by parasiticides (Simparica Trio) and OA pain products (Lenivia, Portela), offering diversification away from U.S. weakness
- Zoetis/Livestock Upside↓ (OPPORTUNITY)◆
U.S. livestock sales grew 23% YoY on favorable beef cattle economics and poultry vaccine demand, a bright spot that could offset companion animal softness
- Danaher/Insider Accumulation↓ (OPPORTUNITY)◆
Chairman and EVP equity awards (500K shares each for Rales brothers) signal strong insider confidence; potential for long-term value creation
- Moderna/Institutional Support↓ (OPPORTUNITY)◆
Fidelity's 13.1% stake increase suggests confidence in pipeline; upcoming clinical catalysts could drive upside
- Biogen/Stable Ownership↓ (OPPORTUNITY)◆
Fidelity's 12.4% stake provides stability; potential for pipeline news to re-rate the stock
- J&J Venture Portfolio (OPPORTUNITY)◆
JJDC's $798.65M portfolio with large positions in Protagonist ($300.2M) and Nanobiotix ($212.0M) offers exposure to high-growth biotech; monitor for milestone-driven gains
- BD/Deferred Compensation Awards (OPPORTUNITY)◆
Director awards at $165.62 suggest fair value; if Q3 results (to be released) show improvement, stock could appreciate
- Zoetis/Shareholder Returns↓ (OPPORTUNITY)◆
Despite earnings decline, aggressive buybacks (EPS up 3.7%) support stock price; if guidance stabilizes, buyback yield could attract value investors
Sector Themes (5)
- Insider Confidence Divergence◆
Danaher insiders received large equity awards (e.g., 1M options each for Rales brothers) while Pfizer and Cigna insiders sold shares, indicating mixed management conviction across healthcare [Pattern: 2 companies with insider selling vs 1 with heavy accumulation]
- Animal Health Headwinds◆
Zoetis's guidance cut and U.S. companion animal decline (-11% YoY) highlight macro-driven price sensitivity and generic competition, a theme likely affecting peers like IDEXX and Elanco [Pattern: 1 major player affected, sector-wide implications]
- Institutional Passive Accumulation◆
Fidelity increased stakes in Moderna (13.1%) and Biogen (12.4%), while First Eagle holds 5.13% in BD, showing passive funds' confidence in large-cap healthcare despite volatility [Pattern: 3 filings showing institutional ownership >5%]
- Capital Allocation Shift◆
Zoetis increased buybacks 48% YoY despite earnings decline, while Danaher uses equity awards for retention, indicating a mix of returning cash and incentivizing leadership [Pattern: 2 companies with distinct strategies]
- Venture Investing in Biotech◆
J&J's JJDC portfolio ($798.65M) focuses on early-to-mid-stage therapeutics, reflecting strategic corporate venture capital trends in healthcare [Pattern: 1 major corporate VC disclosure]
Watch List (8)
-
Q2 2026 results and guidance cut; watch for commentary on U.S. companion animal recovery and any further guidance adjustments (call likely in August 2026)
- BD/Q3 FY2026 Results👁
8-K filed without figures; watch for 10-Q release to assess revenue and margin trends (expected late August 2026)
-
Fidelity's increased stake; watch for clinical trial readouts and FDA decisions in H2 2026
-
Fidelity's 12.4% stake; monitor for Alzheimer's and rare disease program news
-
Large insider awards; watch for strategic moves in bioprocessing and life sciences segments
- J&J Venture Portfolio👁
Monitor Protagonist Therapeutics and Nanobiotix for clinical milestones that could impact JJDC's valuation
-
Further insider selling could signal management concern; watch for additional Form 4 filings
-
Continued insider sales may indicate lack of confidence; monitor for larger transactions
Filing Analyses
(25)
06-08-2026
06-08-2026
06-08-2026
Zoetis reported Q2 2026 revenue of $2.5 billion, flat YoY, with net income of $691 million (down 5% reported) and adjusted net income of $781 million (down 1% reported, down 2% organic operational). U.S. segment revenue declined 7% due to softer companion animal demand and competition, while International segment grew 8% reported (6% organic). The company revised full-year 2026 guidance downward, expecting organic operational revenue growth of (3)% to (1)% and adjusted net income growth of (9)% to (5)%, reflecting persistent market headwinds.
- · U.S. companion animal product sales declined 11% YoY due to softer end-market demand, macro-driven price sensitivity, heightened competition, and generic competition on Cerenia and Convenia.
- · U.S. livestock product sales increased 23% YoY, supported by favorable beef cattle producer economics and increased poultry vaccine sales tied to disease outbreaks.
- · International segment companion animal product sales grew 8% reported (5% organic), led by parasiticides (Simparica Trio, Revolution, Stronghold) and OA pain products Lenivia and Portela.
- · International livestock product sales grew 8% reported (6% organic), driven by cattle and poultry.
- · Zoetis completed the acquisition of VitalRADS, a veterinary teleradiology services platform, in July 2026.
- · The company received marketing authorization from the European Commission for Poulvac Procerta HVT-ND in July 2026.
- · Dectomax-CA1 received FDA conditional approval for prevention/treatment of New World screwworm myiasis in beef cattle; Dectomax received emergency use authorization in the U.S. for other species.
- · Full-year 2026 guidance: reported diluted EPS $5.55-$5.65; adjusted diluted EPS $6.15-$6.25.
- · Zoetis published its 2025 Sustainability Report, completing initial Driven to Care aspirations and introducing the next phase.
- · The Zoetis Foundation fulfilled its commitment to distribute $35 million in grants from 2021 to 2025.
06-08-2026
Becton, Dickinson and Company (BD) reported its financial results for the third fiscal quarter ending June 30, 2026, via a press release furnished as Exhibit 99.1. The release includes non-GAAP measures alongside GAAP results. The filing does not provide specific financial figures, so no period-over-period comparisons or performance trends can be extracted from the 8-K itself.
- · The press release (Exhibit 99.1) contains non-GAAP financial measures with details on adjustments provided in accompanying schedules.
- · The filing is furnished under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits).
06-08-2026
FMR LLC filed an amended Schedule 13G with the SEC, disclosing beneficial ownership of 46,378,258.61 shares of Boston Scientific Corp common stock as of June 30, 2026, representing 3.1% of outstanding shares. The filing is a routine disclosure of passive investment, with no change in control intent.
- · FMR LLC's ownership of 3.1% is below the 5% threshold that would require more detailed reporting.
- · The filing is made pursuant to Rule 13d-1(b), indicating passive investment intent.
- · The Johnson family, including Abigail P. Johnson, holds 49% voting power of FMR LLC through Series B shares and a voting agreement.
- · The filing includes a joint filing agreement under Rule 13d-1(k)(1).
06-08-2026
FMR LLC and Abigail P. Johnson filed an amended Schedule 13G with the SEC, disclosing beneficial ownership of 18,294,523.51 shares of Biogen Inc. common stock as of June 30, 2026, representing 12.4% of outstanding shares. The filing is a routine disclosure of passive investment holdings and does not indicate any change in control or investment intent.
- · FMR LLC is a Delaware limited liability company with principal offices at 245 Summer Street, Boston, Massachusetts.
- · The filing is made pursuant to Rule 13d-1(b) under the Securities Exchange Act of 1934.
- · Fidelity Management & Research Company LLC beneficially owns 5% or more of the outstanding shares of Biogen Inc.
- · Abigail P. Johnson and the Johnson family hold 49% of the voting power of FMR LLC through Series B voting common shares.
- · The filing includes a Rule 13d-1(k)(1) joint filing agreement dated August 5, 2026.
- · The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Biogen Inc.
06-08-2026
FMR LLC (Fidelity) filed a Schedule 13G/A with the SEC on August 6, 2026, reporting beneficial ownership of 51,803,891 shares of Moderna, Inc. common stock as of June 30, 2026, representing a 13.1% stake. This is an amendment to a previous filing, indicating a change in Fidelity's holdings in the biotech company.
- · Filing date: August 6, 2026; period ended: June 30, 2026.
- · FMR LLC is a Delaware corporation with business address at 245 Summer Street, Boston, MA 02210.
- · Abigail P. Johnson is the Chairman and CEO of FMR LLC; the Johnson family holds 49% voting power of FMR LLC through Series B voting common shares.
- · Fidelity Management & Research Company LLC beneficially owns 5% or greater of the outstanding shares.
- · The filing is made pursuant to Rule 13d-1(b) and includes a joint filing agreement under Rule 13d-1(k)(1).
06-08-2026
Johnson & Johnson's venture arm, JJDC, disclosed its Q2 2026 equity holdings in 15 biotech companies, with a total reported market value of approximately $798.65 million. The portfolio is concentrated in early-to-mid-stage therapeutics and diagnostics, with the largest positions in Nanobiotix ($212.0M), Protagonist Therapeutics ($300.2M), and MeiraGTx ($89.7M). While several holdings show significant value, the portfolio also includes smaller, higher-risk positions such as Adicet Bio ($196.8K) and Standard BioTools ($256.7K), reflecting a balanced venture investment strategy.
- · All 15 positions are listed as 'DFND' (defined) and none are put/call options.
- · The filing is for the period ending June 30, 2026, filed on August 6, 2026.
- · The largest single holding by value is Protagonist Therapeutics at $300.2M, followed by Nanobiotix at $212.0M.
- · The smallest positions are Adicet Bio ($196.8K) and Standard BioTools ($256.7K), indicating exploratory or de minimis investments.
- · Cerebras Systems is a notable non-biotech holding, focused on AI computing hardware.
06-08-2026
The filing reports the departure of a director, Dr. Michael B. McCallister, who did not stand for re-election at the 2026 Annual Meeting of Shareholders, effective May 7, 2026. His departure is a routine retirement and not due to any disagreement with the company. The board reduced its size from 13 to 12 directors. The filing also includes the approval of the 2026 Equity and Incentive Plan and the 2026 Employee Stock Purchase Plan, which are routine compensatory arrangements. No negative metrics or performance declines are reported.
- · The director's departure was not due to any disagreement with the company on any matter relating to the company's operations, policies, or practices.
- · The board reduced its size from 13 to 12 directors effective May 7, 2026.
- · The 2026 Equity and Incentive Plan authorizes up to 10,000,000 shares of common stock for issuance.
- · The 2026 Employee Stock Purchase Plan authorizes up to 3,000,000 shares of common stock for issuance.
- · The filing includes the company's press release dated August 6, 2026, announcing the director's retirement.
06-08-2026
SVP & Controller DAMICO JENNIFER B. sold 3,278 Common Stock at $25.40 (~$83.3K). DAMICO JENNIFER B. holds 28,611 shares after the transaction.
- · SVP & Controller DAMICO JENNIFER B. sold 3,278 Common Stock at $25.40 (~$83.3K)
06-08-2026
Zoetis Inc. reported Q2 2026 revenue of $2,468M, essentially flat (-0.2%) compared to $2,474M in Q2 2025, while net income attributable to Zoetis decreased 4.8% to $691M from $726M. For the first half of 2026, revenue grew 1.2% to $4,730M from $4,672M, but net income fell 2.7% to $1,292M from $1,328M. The company continued aggressive share repurchases ($1,170M in H1 2026 vs $788M in H1 2025), boosting diluted EPS by 3.7% to $3.08 despite lower net income.
- · Restructuring charges surged to $99M in H1 2026 from $30M in H1 2025, a 230% increase.
- · Interest expense rose 15% to $123M in H1 2026 from $107M in H1 2025.
- · Operating cash flow declined 5.7% to $1,056M in H1 2026 from $1,120M in H1 2025.
- · Capital expenditures decreased 29.9% to $227M in H1 2026 from $324M in H1 2025.
- · Cash and cash equivalents fell 39.8% from $2,450M at Dec 31, 2025 to $1,476M at June 30, 2026.
- · Total equity decreased 7.8% from $3,415M at Dec 31, 2025 to $3,148M at June 30, 2026.
- · Total assets decreased 2.7% from $15,490M at Dec 31, 2025 to $15,077M at June 30, 2026.
- · The company repurchased 11.0 million shares in H1 2026 vs 4.8 million in H1 2025.
- · Dividends declared per share increased 6% to $0.530 in Q2 2026 from $0.500 in Q2 2025.
- · The prior period figures were recast due to immaterial adjustments; Q2 2025 revenue was increased by $14M and net income by $8M.
06-08-2026
06-08-2026
See Remarks Jones Nicole S sold 19,436 Common Stock, $.01 Par Value at $276.27 (~$5.37M). 5 transactions reported in total. Jones Nicole S holds 28,557 shares after the transaction. Trades executed under a Rule 10b5-1 plan.
- · See Remarks Jones Nicole S exercised/converted 14,045 Common Stock, $.01 Par Value at $192.02 (~$2.7M)
- · See Remarks Jones Nicole S sold 19,436 Common Stock, $.01 Par Value at $276.27 (~$5.37M)
- · See Remarks Jones Nicole S exercised/converted 1,301 Common Stock, $.01 Par Value at $192.02 (~$250K)
- · See Remarks Jones Nicole S exercised/converted 14,045 Employee Stock Option (Right to Buy)
- · See Remarks Jones Nicole S exercised/converted 1,301 Employee Stock Option (Right to Buy)
06-08-2026
Director Huffines Robert Luther was awarded 189 Rights to Common Stock Under BD Deferred Compensation Plan at $165.62 (~$31.3K).
- · Director Huffines Robert Luther was awarded 189 Rights to Common Stock Under BD Deferred Compensation Plan at $165.62 (~$31.3K)
06-08-2026
Director Byington Carrie L was awarded 94 Rights to Common Stock Under BD Deferred Compensation Plan at $165.62 (~$15.6K).
- · Director Byington Carrie L was awarded 94 Rights to Common Stock Under BD Deferred Compensation Plan at $165.62 (~$15.6K)
06-08-2026
Chairman RALES STEVEN M was awarded 500,000 Common Stock, par value $.01. RALES STEVEN M holds 3,605,808 shares after the transaction.
- · Chairman RALES STEVEN M was awarded 500,000 Common Stock, par value $.01
- · Chairman RALES STEVEN M was awarded 1,000,000 Stock option (right to buy)
06-08-2026
Chairman of Exec. Committee RALES MITCHELL P was awarded 500,000 Common Stock, par value $.01. RALES MITCHELL P holds 553,228 shares after the transaction.
- · Chairman of Exec. Committee RALES MITCHELL P was awarded 500,000 Common Stock, par value $.01
- · Chairman of Exec. Committee RALES MITCHELL P was awarded 1,000,000 Stock option (right to buy)
06-08-2026
Executive Vice President Riley Christopher Paul was awarded 41,072 Common Stock. Riley Christopher Paul holds 61,472 shares after the transaction.
- · Executive Vice President Riley Christopher Paul was awarded 41,072 Common Stock
06-08-2026
EVP & Chief Financial Officer Gugino Matthew E was awarded 153,563 Employee stock option (right to buy).
- · EVP & Chief Financial Officer Gugino Matthew E was awarded 153,563 Employee stock option (right to buy)
06-08-2026
SVP, Chief Science Officer Gutierrez-Ramos Jose-Carlos was awarded 13,477 Common Stock. Gutierrez-Ramos Jose-Carlos holds 32,495 shares after the transaction.
- · SVP, Chief Science Officer Gutierrez-Ramos Jose-Carlos was awarded 13,477 Common Stock
06-08-2026
Executive Vice President Sawyer Montgomery Julie A was awarded 245,701 Employee stock option (right to buy).
- · Executive Vice President Sawyer Montgomery Julie A was awarded 245,701 Employee stock option (right to buy)
06-08-2026
SVP-Chief Legal Officer Leiken Jonathan was awarded 92,138 Employee stock option (right to buy).
- · SVP-Chief Legal Officer Leiken Jonathan was awarded 92,138 Employee stock option (right to buy)
06-08-2026
Executive Vice President Milosevich Gregory M was awarded 15,402 Common Stock. Milosevich Gregory M holds 24,467 shares after the transaction.
- · Executive Vice President Milosevich Gregory M was awarded 15,402 Common Stock
06-08-2026
VP, Chief Accounting Officer Bouda Christopher was awarded 12,286 Employee stock option (right to buy).
- · VP, Chief Accounting Officer Bouda Christopher was awarded 12,286 Employee stock option (right to buy)
06-08-2026
First Eagle Investment Management, LLC disclosed a 5.13% beneficial ownership stake in Becton Dickinson & Co (BDX) as of June 30, 2026, holding 14,138,027 shares. The filing is a routine Schedule 13G by a registered investment adviser, indicating passive investment intent without control influence.
- · First Eagle has sole voting power over 12,845,517 shares and sole dispositive power over 14,138,027 shares.
- · The filing is made under Rule 13d-1(b), confirming passive investment intent.
- · Shares are held on behalf of investment advisory clients, including registered investment companies, pension funds, and other institutional clients.
Get daily alerts with 11 investment signals, 8 risk alerts, 8 opportunities and full AI analysis of all 25 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: S&P 500 Healthcare Sector SEC Filings
🇺🇸 More from United States
View all →August 07, 2026
US Pre-Market SEC Filings Roundup — August 07, 2026
US Pre-Market SEC Filings Roundup
August 07, 2026
USA Corporate Events Calendar — August 07, 2026
USA Corporate Events Calendar
August 07, 2026
USA Earnings Calls Schedule — August 07, 2026
USA Earnings Calls Schedule
August 07, 2026
US Merger & Acquisition SEC Filings — August 07, 2026
US Merger & Acquisition SEC Filings